Patrick Soon-Shiong

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Retrieved on: 
Tuesday, January 2, 2024

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.

Key Points: 
  • ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.
  • The proceeds will also be used to fund ongoing business operations and clinical trials expanding N-803 (Anktiva®) indications into multiple solid tumors.
  • Oberland Capital has also an option to purchase an additional $10 million of common stock at a future date.
  • Jefferies LLC acted as exclusive financial advisor to the Company on the transaction.

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities

Retrieved on: 
Monday, September 11, 2023

The new $200 million convertible note with Nant Capital has a three-year term and is convertible into shares of ImmunityBio common stock at a conversion price of a fifty percent (50%) premium over the closing market price immediately preceding the date of the note.

Key Points: 
  • The new $200 million convertible note with Nant Capital has a three-year term and is convertible into shares of ImmunityBio common stock at a conversion price of a fifty percent (50%) premium over the closing market price immediately preceding the date of the note.
  • In addition, the financing transactions restructure the Company’s existing debt obligations with the Nant entities, including an extension of the nearest term debt maturities by one year to December 2024.
  • “With this additional financing, we are well positioned to execute on our commercialization plans in anticipation of the approval of N-803 plus BCG in bladder cancer.
  • We recognize the enormity of such a challenge and this investment will enable the scientists and physicians to pursue the goal of potentially curing cancer in our lifetime.”

NantStudios Builds Groundbreaking Virtual Production Stages in Australia; World’s Largest LED Volume

Retrieved on: 
Monday, March 13, 2023

NantStudios , a leading technology-driven virtual production studio based in Los Angeles, announced today that the company, through its wholly owned Australian subsidiary, has built two new LED in-camera VFX stages at Docklands Studios located in Melbourne, Australia, and will operate the world’s largest LED volume .

Key Points: 
  • NantStudios , a leading technology-driven virtual production studio based in Los Angeles, announced today that the company, through its wholly owned Australian subsidiary, has built two new LED in-camera VFX stages at Docklands Studios located in Melbourne, Australia, and will operate the world’s largest LED volume .
  • View the full release here: https://www.businesswire.com/news/home/20230313005280/en/
    UCP, a division of Universal Studio Group, and Matchbox Pictures chose NantStudios as the virtual production vendor for upcoming projects set to shoot in the State of Victoria.
  • The NantStudios stages will be available to both local and international productions considering locating in Australia’s State of Victoria.
  • NantStudios is led by Michele B. Chan Soon-Shiong, President; Gary Marshall, VP, of Virtual Production; and Keaton Heinrichs, VP, of Operations & Business Development, and is part of the NantWorks ecosystem of companies.

NantHealth Announces $22.5 Million New Financing with Highbridge and Nant Capital

Retrieved on: 
Monday, March 6, 2023

The company intends to use the proceeds to continue funding its existing businesses and for general corporate purposes.

Key Points: 
  • The company intends to use the proceeds to continue funding its existing businesses and for general corporate purposes.
  • The Term Loan Facility was funded by two existing NantHealth investors: Highbridge Capital Management, LLC and Nant Capital, LLC.
  • NantHealth has stood at the forefront of driving evidence based, low cost care to treat the right patient at the right time and the right place.
  • We are pleased at the continued support of NantHealth at this transformational time in healthcare,” said Dr. Patrick Soon-Shiong, Chairman and CEO, NantHealth.

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor

Retrieved on: 
Monday, December 12, 2022

If fully exercised the warrants could result in additional gross proceeds of up to $60 million.

Key Points: 
  • If fully exercised the warrants could result in additional gross proceeds of up to $60 million.
  • The warrants will become immediately exercisable at any time after they are issued and expire two years after the initial issuance date.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

Retrieved on: 
Monday, February 14, 2022

The data showed sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ (NMIBC CIS) bladder cancer (Cohort A) and with papillary disease (Cohort B).

Key Points: 
  • The data showed sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ (NMIBC CIS) bladder cancer (Cohort A) and with papillary disease (Cohort B).
  • In the papillary disease arm of the study (Cohort B), 57% of patients are disease free at 12 months and 53% at 18 months.
  • This study suggests that BCG induces trained immunity as the prime, while N-803 serves as a vital boost for innate immune memory.
  • The latest data from this trial exceeds AUA-FDA workshop benchmarks for both the magnitude of complete remission and the duration of complete response for new therapies for BCG-unresponsive bladder cancer.

Announcement of Upcoming Launch of Access to Advanced Health Institute and The AAAH Coalition

Retrieved on: 
Wednesday, January 19, 2022

Today the Access to Advanced Health Institute (AAHI) announced its upcoming launch and central role in a new global coalition, Africas Access to Advanced Healthcare (AAAH).

Key Points: 
  • Today the Access to Advanced Health Institute (AAHI) announced its upcoming launch and central role in a new global coalition, Africas Access to Advanced Healthcare (AAAH).
  • The AAAH Coalition is supported through several billion rand funding from Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of NantWorks, and from the Chan Soon-Shiong Family Foundation.
  • With the technologies and facilities AAHI brings to the AAAH coalition, we can transform that commitment into real change for the people of Africa."
  • Our name, Access to Advanced Health Institute, reflects our ongoing emphasis on advancing science that enables global access to effective, efficient, broad, and durable preventive and therapeutic solutions.

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date

Retrieved on: 
Wednesday, October 13, 2021

The majority of participants in the study to date remain on therapy and 90% (43/48) of the evaluable patients have exceeded the approximately two-month historical survival rate.

Key Points: 
  • The majority of participants in the study to date remain on therapy and 90% (43/48) of the evaluable patients have exceeded the approximately two-month historical survival rate.
  • had progressed after three to six prior lines of therapy) and, of these patients, 20 out of 23 (87%) have exceeded historical survival rates.
  • It is gratifying to note that patients in this study, who had progressed after up to six lines of prior therapy, have exceeded historical survival rates despite having very advanced pancreatic cancer upon enrollment.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients

Retrieved on: 
Monday, June 28, 2021

The pipeline is described in Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy, which recently published in the Journal for Immunotherapy of Cancer.

Key Points: 
  • The pipeline is described in Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy, which recently published in the Journal for Immunotherapy of Cancer.
  • In clinical use, this neoepitope discovery system supports the targeted delivery of antigens with ImmunityBios second-generation Adeno platform.
  • The future of immunotherapy is in a personalized approach, said Dr. Patrick Soon-Shiong, Founder and Executive Chairman of ImmunityBio.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference

Retrieved on: 
Monday, May 24, 2021

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that Founder and Executive Chairman Dr. Patrick Soon-Shiong will deliver a company presentation at the 2021 Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021.

Key Points: 
  • ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that Founder and Executive Chairman Dr. Patrick Soon-Shiong will deliver a company presentation at the 2021 Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021.
  • Management will be available during the conference for virtual one-on-one meetings.
  • Following the presentation, a live video webcast may be accessed through the Investor Relations section of the ImmunityBio website, www.ir.immunitybio.com .
  • ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases.